The predisposition to and the course of type 2 diabetes vary according to ethnic group ([@B1][@B2]--[@B3]). In Japan, the incidence of type 2 diabetes has increased recently and is now comparable to that of other countries; this is supposedly attributable to the gradual spread of Western habits, such as consuming a high-fat diet, and the lower insulin secretory capacity of Japanese subjects ([@B4],[@B5]). Recent technological developments have allowed the successful identification of gene regions involved in the development of type 2 diabetes in genome-wide association (GWA) studies ([@B6][@B7][@B8][@B9][@B10][@B11][@B12][@B13][@B14][@B15][@B16]--[@B17]). Several susceptibility gene loci identified by GWA studies to date have been used to obtain reproducible evidence of disease association in different populations of European descent and Asians, but not necessarily in African Americans ([@B18][@B19][@B20][@B21][@B22][@B23]--[@B24]). A number of GWA studies on type 2 diabetes have been conducted on populations of European descent ([@B6][@B7][@B8][@B9][@B10][@B11]--[@B12]). Two GWA scans in the Japanese population simultaneously reported the discovery of type 2 diabetes susceptibility gene (*KCNQ1*) variants in non-European populations; this result was also obtained in Scandinavian samples ([@B25],[@B26]). Thus far, the replicated associations for a limited number of candidate genes have broadly indicated the tendency of interethnic similarity. Even though the common (or cosmopolitan) effect of type 2 diabetes risk variants is known, the extent to which the causation of this disease differs or overlaps between populations remains unknown. Here, besides comparing the genetic associations between European-descent and Japanese populations, we aimed to identify new genetic variants using a three-staged GWA study design.

RESEARCH DESIGN AND METHODS
===========================

Detailed characteristics of the subjects enrolled in each stage are described in the supplementary information and in supplementary Table S1, which is available in an online appendix at <http://diabetes.diabetesjournals.org/cgi/content/full//db08-1494/DC1>. Briefly, patients and unaffected control subjects analyzed in stages 1 and 2 were enrolled depending on whether they met certain uniform criteria. Type 2 diabetes was diagnosed according to 1999 World Health Organization criteria. All stage 1 and 2 control subjects (≥55 years of age at examination) had normal glucose tolerance. The stage 3 samples comprised 4,000 type 2 diabetes case subjects derived from the Biobank Japan project (<http://biobankjp.org/>) ([@B27]) and 12,569 subjects randomly selected from residents aged 50--74 years in the general population. The 12,569 subjects were used as a population panel; this panel contained 4,889 nondiabetic subjects who met the following conditions: age ≥55 years, A1C ≤5.0%, no previous and/or current treatment for diabetes, and absence of renal failure (serum creatinine \<3.0 mg/dl). In stage 3, these 4,889 control subjects were used in a replication study wherein their genotypes were compared with those of 4,000 patients. In addition to the samples genotyped here, to boost the power of the GWA scan, we incorporated genotype frequencies in the general Japanese population (*n* = 964) derived from the Genome Medicine Database of Japan (GeMDBJ; <http://gemdbj.nibio.go.jp>), which was used as an in silico control panel. A flowchart summarizing the multistage design and study aims is shown in [Fig. 1](#F1){ref-type="fig"}.

Stage 1 genome-wide scan and quality control.
---------------------------------------------

Genotyping was performed with the Infinium HumanHap550 BeadArray (Illumina), which interrogated 555,352 SNPs (supplementary information). The average call rate was 96.9% for the case and control subjects. Data cleaning and analysis were performed using PLINK software ([@B28]). Samples with a genotype call rate of \<90% were excluded, as were outliers with respect to the number of heterozygous SNPs, duplicates or relatives of another sample, or ethnic outliers. We excluded SNPs for the following reasons: *1*) GenTrain genotype quality score \<0.53, *2*) genotype call rate \<0.95, *3*) genotype call rate \<0.99 and minor allele frequency (MAF) \<0.05, *4*) significant (*P* \< 10^−6^) deviation from the Hardy-Weinberg equilibrium in the control subjects, or *5*) MAF \<0.001 (supplementary Table S2); the remaining 482,625 SNPs were analyzed.

Analysis of stage 1 genotype data.
----------------------------------

Ethnicity was verified for 1,022 samples (519 case and 503 control subjects) in the stage 1 panel with reference to data from HapMap populations ([@B29]) (see supplementary information). Type 2 diabetes association was tested with the Cochran-Armitage trend test in the stage 1 panel and an additional panel of 964 random control subjects. We pooled the genotype counts for combining multiple panels. To detect and correct population stratification and unnoticed differences in data processing between facilities, the test statistic was adjusted using Eigenstrat software ([@B30]) and the genomic-control method ([@B31]). The significance level for the first-stage scan was set to *P* \< 0.0025; significant SNPs were additionally chosen using Fisher\'s χ^2^ test (*P* \< 0.0025) to combine the association results with the *P* value at the same locus in our previous affected sib-pair scan ([@B32]). A total of 1,811 SNPs surpassed the stage 1 threshold, and we removed redundant SNPs that were in mutual strong linkage disequilibrium (*r*^2^ \>0.9) before proceeding to stage 2 (see supplementary information and supplementary Fig. S1 and Table S2 for detailed analysis).

Stage 2 genotyping and analysis.
--------------------------------

Stage 2 genotyping was performed with iPLEX (Sequenom) and GoldenGate (Illumina) assays. Quality control was conducted as described in stage 1, and 1,456 SNPs were successfully genotyped. We calculated *P* values with the trend test by combining 1,517 nondiabetic control subjects with 964 random control subjects similar to stage 1. The significance level for the second-stage scan was set to *P* \< 7 × 10^−5^ in the comparison between 1,629 case subjects and 2,481 control subjects (i.e., the stage 1 + 2 panels and the 964 random control subjects). A total of 30 SNPs representing 17 unique loci remained significant.

Replication of previously reported SNPs.
----------------------------------------

Along with genome-wide exploration, type 2 diabetes association was tested in the stage 1 and 2 panels using the HumanHap550 BeadArray, iPLEX assay, or TaqMan method (Applied Biosystems) for 17 SNPs from 16 candidate loci previously identified by GWA studies in populations of European descent ([@B6][@B7][@B8][@B9][@B10][@B11][@B12][@B13][@B14][@B15][@B16]--[@B17]). These included *IGF2BP2* (rs4402960), *PPARG* (rs1801282), *CDKAL1* (rs7754840 and rs7756992), *SLC30A8* (rs13266634), *CDKN2A*/*CDKN2B* (rs10811661), *HHEX* (rs1111875), *TCF7L2* (rs7903146), *EXT2* (rs3740878), *KCNJ11* (rs5219), *FTO* (rs8050136), *JAZF1* (rs864745), *CDC123-CAMK1D* (rs12779790), *TSPAN8-LGR5* (rs7961581), *THADA* (rs7578597), *ADAMTS9* (rs4607103), and *NOTCH2-ADAM30* (rs10923931). The significant SNPs (trend test, *P* \< 0.05) were further analyzed in the stage 3 panel with the TaqMan method. Despite finding significant association for *CDKAL1* and *CDKN2A*/*CDKN2B* in the stage 1 and 2 panels, we proceeded with rs4712523 instead of rs7754840 and rs7756992 (*CDKAL1*) and with rs2383208 instead of rs10811661 (*CDKN2A*/*CDKN2B*) in the GWA scans from stage 1 to stage 3; this decision was made considering the strong linkage disequilibrium between the SNPs in each of the corresponding loci.

Stage 3 genotyping and analysis.
--------------------------------

The stage 3 design involved the replication of association and the estimation of effect sizes in the GWA scan and/or replication study of previously reported SNPs. For an association to be considered significant in the case-control comparison (4,000 case vs. 4,889 nondiabetic control subjects), it had to involve the same risk allele as that in the previous stages, and it was accordingly assessed with a one-tailed test. For each SNP locus confirmed in stage 3, the association of additional independent SNPs or haplotypes in the locus was also tested (supplementary information). Moreover, to assess the risk of diabetes and pre-diabetes in the general population from the combination of SNPs robustly confirmed both in populations of European descent and in our panel, multiple regression analysis was performed with the logarithm of A1C (log A1C) as a response variable (supplementary information), using the entire 12,569-subject population-based sample.

Meta-analysis of other type 2 diabetes case-control studies in the Japanese population.
---------------------------------------------------------------------------------------

In addition, for SNPs with robustly confirmed association in populations of European descent, we performed a meta-analysis by combining our stage 1 + 2 (rs1801282, rs7756992, and rs8050136) or stage 1 + 2 + 3 results (the remaining seven SNPs shown in supplementary Figure S2) with those of previous Japanese studies conducted by three other groups ([@B19][@B20]--[@B21],[@B33][@B34][@B35]--[@B36]). According to Woolf\'s test ([@B37]), the heterogeneity among the studies in the Japanese population was insignificant (*P* \> 0.05), with the exception of *PPARG* rs1801282 (*P* = 0.0012), for which the observed heterogeneity is supposedly attributable to low allele frequency. Thus, we pooled genotype counts across the studies to form a combined dataset for the Japanese population, and we estimated the effect sizes of individual loci. We used the rmeta package for R software (<http://www.r-project.org>) for the analysis.

Moreover, to compare the explained variance between the Japanese population and populations of European descent, we calculated the coefficient of determination *R* ^2^ for the loci confirmed in our replication study. Here, *R^2^* is the square of the correlation between the genotypes of an SNP coded by the number of risk alleles (0, 1, and 2) and the disease status (0 and 1) (supplementary information).

RESULTS
=======

GWA scans.
----------

Of 482,625 SNPs that passed quality control in stage 1, genotypes were obtained for an average of 99.8% markers for each subject. The subjects were enrolled from regions of Japan with no strong population stratification ([@B38]), and although some variance inflation partly attributable to the subtle subpopulation structure was apparent, such confounding influences could be sufficiently removed using Eigenstrat ([@B30]) and genomic-control adjustment ([@B31]). A total of 1,456 markers were assessed in the stage 2 panel ([Fig. 1](#F1){ref-type="fig"} and supplementary Fig. S1 and Table S2).

![Flow chart summarizing the multistage design and study aims. (A high-quality digital representation of this figure is available in the online issue.)](zdb0070957930001){#F1}

After the second-stage scan, 30 SNPs representing 17 unique loci attained the arbitrarily defined statistical significance (*P* \< 7 × 10^−5^) (supplementary Table S3). We used one SNP each from these 17 loci in the third-stage scan. Of 17 SNPs, 4 reached the significance threshold of *P* \< 0.003 (= 0.05/17) with Bonferroni correction.

The current GWA study showed strong and highly consistent evidence for disease association of SNPs from *CDKAL1*, *CDKN2A*/*CDKN2B*, and *KCNQ1* ([Fig. 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"} and supplementary Tables S4 and S5). Although these three loci had already been reported in previous GWA studies ([@B8],[@B11],[@B25],[@B26]), here they were identified as part of our genome-wide exploration. *CDKAL1* is among the best-replicated susceptibility loci. Significant association has also been detected in a region on chromosome 9p, near *CDKN2A*/*CDKN2B*. Moreover, strong association signals were observed in the intron of *KCNQ1* on chromosome 11p15.5, which is in agreement with the results of two previous GWA scans in the Japanese population ([@B25],[@B26]).

![Plots of type 2 diabetes association and linkage disequilibrium for regions surrounding *CDKAL1* (*A*), regions near *CDKN2A/CDKN2B* (*B*), and *KCNQ1* (*C*). *A*, *B*, and *C* each contain five panels. In the top panels, all genotyped SNPs in the current Japanese GWA scan (that passed the quality control) are plotted with their −log~10~ (*P* values) for type 2 diabetes (Cochran-Armitage trend test) against chromosome position (in Mb). Blue and red squares indicate *P* values for the combined genotypes of stages 1 + 2 and stages 1 + 2 + 3, respectively, whereas vertical bars indicate *P* values for the stage 1 genotype. In the second panels, −log~10~ (*P* values) plots from the DIAGRAM study of populations of European descent are similarly displayed ([@B17]). The third panels show the genomic location of RefSeq genes with intron and exon structure (NCBI \[National Center for Biotechnology Information\] Build 35). The fourth and fifth panels show a WGAViewer ([@B50]) plot of linkage disequilibrium (*r* ^2^) for all HapMap SNPs across the regions for the HapMap populations---Japanese in Tokyo (JPT) and CEPH subjects from Utah (CEU)---respectively.](zdb0070957930002){#F2}

###### 

Type 2 diabetes susceptibility loci identified or tested for replication in the current Japanese study

  rs no.[\*](#TF1-1){ref-type="table-fn"}   Chromosome   Position (bp)   Region            Risk allele/nonrisk allele   Control risk allele proportion   Stage 1 + 2 (1,629 case subjects/1,517 control subjects)   Stage 3 (4,000 case subjects/4,889 control subjects)[†](#TF1-2){ref-type="table-fn"}   All combined (5,629 case subjects/6,406 control subjects)[†](#TF1-2){ref-type="table-fn"}   OR (95% CI) reported in Europeans (14,586 case subjects/17,968 control subjects)                                 
  ----------------------------------------- ------------ --------------- ----------------- ---------------------------- -------------------------------- ---------------------------------------------------------- -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ------------------- --------- ---------------------------------------------------
  Identified in this GWA scan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
      rs4712523                             6            20,765,543      *CDKAL1*          G/A                          0.407                            1.38 (1.25--1.52)                                          8.0E-10                                                                                1.23 (1.16--1.30)                                                                           4.0E-12                                                                            1.27 (1.21--1.33)   7.2E-20   1.12 (1.08--1.16)
      rs2383208                             9            22,122,076      *CDKN2A/B*        A/G                          0.553                            1.31 (1.18--1.45)                                          1.6E-07                                                                                1.33 (1.26--1.42)                                                                           4.8E-22                                                                            1.34 (1.27--1.41)   2.1E-29   1.20 (1.14--1.25)
      rs2237892                             11           2,796,327       *KCNQ1*           C/T                          0.594                            1.25 (1.13--1.39)                                          2.3E-05                                                                                1.36 (1.28--1.45)                                                                           8.0E-23                                                                            1.33 (1.27--1.41)   1.1E-26   1.18 (1.03--1.33)[§](#TF1-4){ref-type="table-fn"}
      rs10425678                            19           38,669,236      *PEPD*            C/T                          0.261                            1.23 (1.10--1.37)                                          3.6E-04                                                                                1.10 (1.03--1.18)                                                                           0.0020                                                                             1.14 (1.07--1.20)   1.4E-05   1.03 (0.97--1.09)[§](#TF1-4){ref-type="table-fn"}
  Replication of previously-reported SNPs                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
      rs10923931                            1            120,230,001     *NOTCH2-ADAM30*   T/G                          0.020                            1.17 (0.83--1.65)                                          0.3821                                                                                 ---                                                                                         ---                                                                                ---                 ---       1.13 (1.08--1.17)[‖](#TF1-5){ref-type="table-fn"}
      rs7578597                             2            43,644,474      *THADA*           T/C                          0.990                            1.95 (1.03--3.67)                                          0.0392                                                                                 0.98 (0.73--1.31)                                                                           0.55                                                                               1.13 (0.87--1.47)   0.35      1.15 (1.10--1.20)[‖](#TF1-5){ref-type="table-fn"}
      rs1801282                             3            12,368,125      *PPARG*           C/G                          0.969                            1.00 (0.75--1.34)                                          0.9741                                                                                 ---                                                                                         ---                                                                                ---                 ---       1.14 (1.08--1.20)
      rs4607103                             3            64,686,944      *ADAMTS9*         C/T                          0.594                            1.09 (0.99--1.21)                                          0.0902                                                                                 ---                                                                                         ---                                                                                ---                 ---       1.09 (1.06--1.12)[‖](#TF1-5){ref-type="table-fn"}
      rs4402960                             3            186,994,389     *IGF2BP2*         T/G                          0.310                            1.15 (1.04--1.28)                                          0.0098                                                                                 1.14 (1.07--1.21)                                                                           2.5E-05                                                                            1.14 (1.08--1.21)   1.0E-06   1.14 (1.11--1.18)
      rs7754840                             6            20,769,229      *CDKAL1*          C/G                          0.392                            1.42 (1.28--1.57)                                          1.7E-10                                                                                ---                                                                                         ---                                                                                ---                 ---       1.12 (1.08--1.16)
      rs7756992                             6            20,787,688      *CDKAL1*          G/A                          0.448                            1.35 (1.23--1.50)                                          4.6E-09                                                                                ---                                                                                         ---                                                                                ---                 ---       1.26 (1.18--1.34)[§](#TF1-4){ref-type="table-fn"}
      rs864745                              7            27,953,796      *JAZF1*           T/C                          0.789                            1.08 (0.95--1.22)                                          0.2456                                                                                 ---                                                                                         ---                                                                                ---                 ---       1.10 (1.07--1.13)[‖](#TF1-5){ref-type="table-fn"}
      rs13266634                            8            118,253,964     *SLC30A8*         C/T                          0.570                            1.18 (1.06--1.30)                                          0.0015                                                                                 1.24 (1.17--1.31)                                                                           5.8E-13                                                                            1.22 (1.16--1.28)   1.8E-14   1.12 (1.07--1.16)
      rs10811661                            9            22,124,094      *CDKN2A/B*        T/C                          0.555                            1.35 (1.21--1.49)                                          2.2E-08                                                                                ---                                                                                         ---                                                                                ---                 ---       1.2 (1.14--1.25)
      rs12779790                            10           12,368,016      *CDC123-CAMK1D*   G/A                          0.151                            0.98 (0.85--1.13)                                          0.7984                                                                                 ---                                                                                         ---                                                                                ---                 ---       1.11 (1.07--1.14)[‖](#TF1-5){ref-type="table-fn"}
      rs1111875                             10           94,452,862      *HHEX*            C/T                          0.275                            1.19 (1.07--1.33)                                          0.0011                                                                                 1.21 (1.13--1.29)                                                                           2.6E-09                                                                            1.21 (1.15--1.28)   6.7E-12   1.13 (1.09--1.17)
      rs7903146                             10           114,748,339     *TCF7L2*          T/C                          0.035                            1.42 (1.10--1.84)                                          0.0073                                                                                 1.59 (1.38--1.83)                                                                           5.3E-11                                                                            1.54 (1.36--1.74)   7.6E-12   1.37 (1.31--1.43)
      rs5219                                11           17,366,148      *KCNJ11*          T/C                          0.355                            1.22 (1.09--1.35)                                          2.5E-04                                                                                1.02 (0.96--1.08)                                                                           0.3008                                                                             1.07 (1.01--1.13)   0.0149    1.14 (1.10--1.19)
      rs3740878                             11           44,214,378      *EXT2*            A/G                          0.633                            1.01 (0.91--1.12)                                          0.8849                                                                                 ---                                                                                         ---                                                                                ---                 ---       1.20 (1.11--1.30)[¶](#TF1-6){ref-type="table-fn"}
      rs7961581                             12           69,949,369      *TSPAN8-LGR5*     C/T                          0.202                            1.12 (0.99--1.27)                                          0.0751                                                                                 ---                                                                                         ---                                                                                ---                 ---       1.09 (1.06--1.12)[‖](#TF1-5){ref-type="table-fn"}
      rs8050136                             16           52,373,776      *FTO*             A/C                          0.203                            1.11 (0.98--1.26)                                          0.0915                                                                                 ---                                                                                         ---                                                                                ---                 ---       1.17 (1.12--1.22)

Results for one SNP each selected from the individual chromosomal regions in the GWA scans are shown in the Table S4 for details and supplementary Table S5 for the results of logistic regression adjusted for BMI). The final *P* value was assessed by pooling genotype counts for each SNP from all stages tested (without including 964 random control subjects from GeMBDJ). In two regions, chromosome 6p22.3 (*CDKAL1*) and 19p13 (*PEPD*), the haplotype class showed more significant association than the individual SNP (see supplementary Information).

\*In the stage 3 panel, we genotyped rs4712523 instead of rs7754840 (*r* ^2^ = 0.96) or rs7756992 (*r* ^2^ = 0.65) in CDKAL1, and rs2383208 instead of rs10811661 (*r* ^2^ = 0.89) near CDKN2A/B, with the aim of determining the SNP(s) with the strongest association in the Japanese population.

†In stage 3 of the replication study on previously reported SNPs, after the confirmation of significant association in 4,000 case subjects and 4,889 preselected control subjects, we further characterized 7,680 subjects (who comprised the rest of the 12,569 population-based samples) (see [research design and methods]{.smallcaps} and [Fig. 1](#F1){ref-type="fig"}). Thus, for the corresponding SNPs, 5,395 control subjects were reselected from the entire population-based samples and used for the final association analysis in stage 3, which increased the total number of control subjects across the three stages to 6,912.

‡One-tailed test for association was performed in the direction consistent with stage 1 + 2 data;

§for 4,549 case and 5,579 control subjects derived from the DIAGRAM consortium of Zeggini et al. ([@B17]);

‖for ∼60,000 total samples from Zeggini et al. ([@B17]);

¶for 3,278 case and 3,508 control subjects from Sladek et al. ([@B6]).

Stage 2 genotyping provided evidence suggestive of a new association on chromosome 19q13. Several SNPs located in the vicinity of the *PEPD* (peptidase D) gene showed the tendency of replicated association in stages 1 and 2 (supplementary Table S3). Significant association was further replicated in a relatively large case-control study on the stage 3 panel (rs10425678, *P* = 0.002), but it did not attain genome-wide significance (i.e., *P* = 1.4 × 10^−5^ for all stages and *P* = 2.1 × 10^−6^ when the number of control subjects was increased by adding 964 random control subjects) (supplementary Table S4). Given the modest strength of association (*R* ^2^ = 0.0017, see below) assumed for this locus, the association still needs to be established.

Replication of previously reported SNPs.
----------------------------------------

Of 16 candidate loci tested for replication in the Japanese population, 7 were found to be associated with type 2 diabetes ([Table 1](#T1){ref-type="table"}). However, no significant association was observed for SNPs from the remaining nine loci (*FTO*, *PPARG*, *EXT2*, *JAZF1*, *CDC123-CAMK1D*, *TSPAN8-LGR5*, *ADAMTS9*, and *NOTCH2-ADAM30* in the stage 1 + 2 panel and *THADA* in the stage 1 + 2 + 3 panel). Notably, the originally reported SNPs or those in complete linkage disequilibrium showed the strongest statistical evidence of association in the seven confirmed loci, where the linkage disequilibrium relations and haplotype patterns appear to be similar but not identical between European-descent and Japanese populations (supplementary Figs. S3 and S4).

Besides *KCNQ1* and the 16 candidate loci prioritized here, we investigated the disease association of two candidate gene SNPs---rs734312 in *WFS1* ([@B39]) and rs7501939 in *TCF2* ([@B40])---based on the genotype data of our stage 1 panel (*n* = 1,022) and 964 random control subjects (supplementary Table S6). In some instances, it appeared that the sample size was not sufficient to detect the presumed odds ratio (OR) (supplementary Table S7). Nevertheless, except for rs12779790 in *CDC123-CAMK1D* and rs3740878 in *EXT2*, in the majority of instances, the ORs were consistent with those previously reported. Furthermore, we analyzed seven previously reported SNPs with suggestive evidence of an association in the Japanese population ([@B25]), but none attained nominal significance in our first-stage scan (supplementary Table S8).

Ethnic differences in genetic effects on type 2 diabetes.
---------------------------------------------------------

With regard to the candidate gene SNPs robustly confirmed in GWA studies conducted on Japanese and European-descent populations, we compared the risk allele frequency and OR between the meta-analysis dataset of the Japanese population and that of populations of European descent ([@B8][@B9]--[@B10]) ([Fig. 3](#F3){ref-type="fig"}). The OR was consistently higher in the Japanese population for all SNPs except rs5219 in *KCNJ11*. Among the confirmed loci, *CDKAL1*, *CDKN2A/CDKN2B*, *SLC30A8*, and *HHEX* showed a significant difference in the ORs between European-descent and Japanese populations (*P* \< 0.05, Woolf\'s test) (supplementary Table S6). However, the risk allele frequency fluctuated between the two ethnic groups, and the strength of association differed accordingly; this is because an SNP with an risk allele frequency of ∼0.5 and a higher OR can give rise to stronger association signals. Thus, whereas *TCF7L2* was shown as the strongest susceptibility locus in populations of European descent ([@B41]), its association is estimated to be much weaker in the Japanese population because of the low risk allele frequency. In contrast, the results of the meta-analysis showed that the *CDKN2A/CDKN2B* and *CDKAL1* loci had the strongest associations in the Japanese population; indeed, we obtained the highest number of hits for these loci.

![Comparison of the strength of association for seven confirmed type 2 diabetes loci between Japanese and European-descent populations. For the Japanese population, we estimated ORs and their 95% CIs (red solid squares and vertical lines, respectively) for each locus based on our meta-analysis involving four Japanese case-control studies (supplementary Fig. S2). For populations of European descent, on the other hand, the corresponding values (blue solid squares and vertical lines) were derived from the published data ([@B8][@B9]--[@B10]). The association of an SNP with type 2 diabetes is measured by the coefficient of determination (*R* ^2^), which represents the ability to detect association signals using the Cochran-Armitage trend test.](zdb0070957930003){#F3}

Next, we compared the strength of association for the seven confirmed loci between Japanese and European-descent populations and calculated *R* ^2^ as the proportion of phenotypic variance explained by an SNP (see [research design and methods]{.smallcaps}). In [Fig. 3](#F3){ref-type="fig"}, we illustrate the curves corresponding to *R* ^2^ = 0.008, 0.004, and 0.002, for which the total sample size of case and control subjects required to attain 80% power is *n* = 4,300, 8,600, and 17,200 at a significance level of *P* = 5 × 10*^--7^* (which is the significance threshold generally required in GWA tests), and *n* = 1,000, 2,000, and 3,900 at a level of *P* = 0.05. Based on *R* ^2^ measurements using the meta-analysis data, the associations of five of seven replicated loci are stronger in the Japanese population than in populations of European descent. For the *CDKAL1* locus, for example, one-fourth of the sample size necessary in populations of European descent is sufficient to obtain the same level of statistical significance in the Japanese population. This is true for *CDKN2A/CDKN2B*, *HHEX*, and *SLC30A8*, in which \<50% of the sample size seems to be sufficient for significance in the Japanese population. However, *TCF7L2* shows an opposite trend in this regard.

Combined genetic risk of type 2 diabetes.
-----------------------------------------

Despite the small value of explained variance (*R* ^2^) at each risk locus, it is assumed that knowledge about multiple-risk loci could allow us to identify individuals with accumulated genetic risk ([@B42]). To this end, a GWA study in Finns ([@B10]) investigated the combined risk of type 2 diabetes based on 10 associated loci by logistic regression analysis of the resampled dataset. The total variance explained by 10 loci in Finns is *R* ^2^ = 0.030, which is equivalent to the value for 7 loci obtained here (see [discussion]{.smallcaps}). Likewise, in a simulated population, we arranged the individuals in the order of the risk estimated by logistic regression, sorted them into 20 equal-sized groups (5% in each), and calculated the actual proportion of affected individuals in each group. We found a 3.7-fold variation in type 2 diabetes prevalence from the lowest to highest estimated risk groups for the combination of seven associated loci in our study ([Fig. 4](#F4){ref-type="fig"}). The receiver operating characteristic curve was also depicted for the combined SNPs as a measure of sensitivity and specificity (supplementary Fig. S5).

![Estimation of the increase in type 2 diabetes risk from the combination of seven susceptibility variants previously identified and robustly replicated in the current study. We used case and control subjects with complete data from all stages of our study (*n* = 12,105). First, the risk for the genotypes of an SNP was estimated by logistic regression. Then, the multilocus risk for an individual was assessed as the sum of the risks for his/her genotype at seven SNPs. We simulated a population with 10% prevalence by bootstrap sampling. In the simulated population, we arranged the individuals in the order of their multilocus risk, sorted them into 20 equal-sized groups, and calculated the actual prevalence in each group. Means and 95% CIs of the groupwise prevalence were estimated based on 1,000 bootstrap sampling trials and are plotted in the figure. No significant gene-gene interaction was observed between the seven SNPs by multiple logistic regression analysis. T2D, type 2 diabetes.](zdb0070957930004){#F4}

Moreover, for risk assessment in the general population, we performed multiple regression analysis using A1C as a surrogate quantitative phenotype to estimate the unbiased effect size of individual loci (supplementary Table S9) and evaluated the combined risk from multiple loci in 12,569 population-based samples ([Table 2](#T2){ref-type="table"} and supplementary information). Then, the estimated risk was compared with the actual A1C value and the disease classification of diabetes or pre-diabetes (supplementary information). In the multiple regression analysis, significant association (*P* \< 0.005) was observed for all seven loci tested in accordance with the results for the case-control study ([Table 1](#T1){ref-type="table"} and supplementary Table S4). As shown in [Fig. 4](#F4){ref-type="fig"}, 5% of male subjects with the highest estimated risk are 2.3 times more likely to suffer from diabetes than those with the lowest estimated risk; the risk is 5.2 times in female subjects, indicating the potential existence of sex difference in the genetic risk of type 2 diabetes (supplementary Fig. S6). Moreover, notably, SNP genotypes alone exerted more exaggerated effects on the increase in genetic risk in diabetes compared with pre-diabetes ([Table 2](#T2){ref-type="table"}).

###### 

Combined risk of diabetes and pre-diabetic status based on seven confirmed loci, age, BMI, and sex in the general Japanese population

                                                         A1C (%)       Diabetes            Pre-diabetes   Diabetes + Pre-diabetes                              
  ------------------------------------------------------ ------------- ------------------- -------------- ------------------------- ------ ------------------- ------
  Male                                                                                                                                                         
      Whole population                                   5.29 ± 0.88   1.00                0.16           1.00                      0.07   1.00                0.23
      Highest risk group (5%) assessed by                                                                                                                      
          All predictors                                 5.48 ± 0.87   1.65 (1.29--1.97)   0.27           1.34 (0.73--1.83)         0.09   1.56 (1.26--1.78)   0.36
          SNP genotypes                                  5.57 ± 1.12   1.67 (1.32--2.06)   0.27           0.92 (0.44--1.40)         0.07   1.45 (1.16--1.73)   0.34
          Age and BMI[\*](#TF2-1){ref-type="table-fn"}   5.44 ± 0.78   1.16 (0.87--1.46)   0.19           1.95 (1.39--2.60)         0.14   1.40 (1.16--1.65)   0.33
      Lowest risk group (5%) assessed by                                                                                                                       
          All predictors                                 4.98 ± 0.73   0.46 (0.26--0.74)   0.08           0.50 (0.20--0.90)         0.04   0.47 (0.33--0.70)   0.11
          SNP genotypes                                  5.11 ± 0.74   0.72 (0.39--0.92)   0.12           0.71 (0.30--1.10)         0.05   0.72 (0.46--0.86)   0.17
          Age and BMI[\*](#TF2-1){ref-type="table-fn"}   4.98 ± 0.77   0.46 (0.30--0.73)   0.08           0.40 (0.10--0.60)         0.03   0.44 (0.27--0.63)   0.10
  Female                                                                                                                                                       
      Whole population                                   5.17 ± 0.60   1.00                0.07           1.00                      0.06   1.00                0.13
      Highest risk group (5%) assessed by                                                                                                                      
          All predictors                                 5.55 ± 0.96   3.09 (2.36--3.73)   0.22           2.05 (1.37--2.60)         0.13   2.61 (2.10--2.96)   0.35
          SNP genotypes                                  5.37 ± 0.88   2.30 (1.60--2.78)   0.17           1.17 (0.73--1.80)         0.07   1.78 (1.41--2.10)   0.24
          Age and BMI[\*](#TF2-1){ref-type="table-fn"}   5.42 ± 0.78   2.26 (1.71--2.78)   0.16           1.95 (1.34--2.53)         0.12   2.12 (1.73--2.46)   0.28
      Lowest risk group (5%) assessed by                                                                                                                       
          All predictors                                 4.91 ± 0.43   0.16 (0.00--0.32)   0.01           0.14 (0.00--0.28)         0.01   0.15 (0.04--0.26)   0.02
          SNP genotypes                                  5.02 ± 0.45   0.45 (0.16--0.73)   0.03           0.80 (0.38--1.22)         0.05   0.61 (0.35--0.83)   0.08
          Age and BMI[\*](#TF2-1){ref-type="table-fn"}   4.94 ± 0.36   0.24 (0.08--0.64)   0.02           0.19 (0.00--0.37)         0.01   0.22 (0.09--0.47)   0.03

Data are the means ± SD, unless otherwise indicated. Relative risk (RR) is calculated as the ratio of the prevalence in 5% of people with the highest or lowest risk to the prevalence in the whole population. In this study, the combined disease risk for each individual was assessed using the regression for A1C (see supplementary information). Subjects with self-reported diabetes or with A1C ≥6.1 were classified as diabetic, and those who were not under antidiabetic medication and with 5.6 ≤ A1C \< 6.1 were classified as pre-diabetic. The actual A1C level and the distribution by diabetic status for each 5% subgroup of the risk group are illustrated in supplementary Fig. S6.

\*For reference, diabetes and/or pre-diabetes risk was assessed using the participant\'s age and BMI alone as predictors.

DISCUSSION
==========

Conducting GWA studies on a wider range of populations, including East Asians, has recently gained importance because of the discovery of new type 2 diabetes susceptibility variants mapping to the *KCNQ1* gene simultaneously reported in two Japanese studies ([@B25],[@B26]). Both studies were, however, initiated some years ago, and they are, by current standards, considered to be modest with regard to the coverage of common SNPs (21 and 56% in HapMap) and number of case subjects (187 and 194 subjects, respectively) in the first-stage scan. Therefore, we conducted another GWA study on the Japanese population with greater coverage of common SNPs (87% of all phase 1 + 2 HapMap variants \[MAF ≥0.05\] in CHB (Chinese in Beijing) + JPT (Japanese in Tokyo) and a larger number of case subjects (519 subjects) and unaffected control subjects (503 subjects) in addition to random control subjects in the first-stage scan. Four loci (three previously reported and one novel) were identified via the multistage scans. For the top three loci (*KCNQ1*, *CDKN2A/CDKN2B*, and *CDKAL1*) the OR (\>1.25) and MAF (0.41--0.45 in the control subjects) were higher in the Japanese population than in populations of European descent. In addition to the nomination of four susceptibility loci (*KCNQ1*, *CDKN2A/CDKN2B*, *CDKAL1*, and *PEPD*), the current study replicated the significant association of five other loci (*TCF7L2*, *IGF2BP2*, *SLC30A8*, *HHEX*, and *KCNJ11*) previously reported in populations of European descent ([@B6][@B7][@B8][@B9][@B10][@B11][@B12][@B13][@B14][@B15][@B16]--[@B17]) and provided an unbiased estimate of the risk from the confirmed disease genotype.

Empirical studies suggest that the genetic effects of individual causal risk alleles underlying complex genetic diseases such as type 2 diabetes are modest, with most genotype relative risks in the range of 1.1--2.0 ([@B43]). Indeed, we observed this to be true for loci that were robustly implicated in the development of type 2 diabetes by GWA scans and/or extensive candidate gene approaches in populations of European descent. Currently, the number of loci has increased to almost 20 (as listed in supplementary Table S6), and in most cases, except for *TCF7L2* and *KCNQ1*, the OR is estimated to be between 1.09 and 1.20.

The current study provides, via genome-wide exploration and replication analysis of some a priori selected loci, significant evidence for the overall tendency toward a stronger association in Japanese rather than European-descent populations at least for alleles with a cosmopolitan effect. The tendency for higher OR in Asians than in Europeans was previously reported for the *CDKAL1* locus ([@B22]). Currently, it remains unknown whether the penetrance for a genotype of interest differs considerably between Japanese and European-descent populations. With regard to genetic effects, four of seven confirmed loci have demonstrated significantly higher OR in the Japanese population (*P* = 4.1 × 10^−5^ to 0.024) (supplementary Table S6). To simplify the situation, we have further assessed the strength of association for individual SNPs by measuring *R* ^2^, which is scaled against OR and risk allele frequency in [Fig. 3](#F3){ref-type="fig"}. We found that despite the limited number of SNPs tested here, the same level of statistical significance is often detectable in the Japanese population with a much smaller sample size than that in populations of European descent (supplementary Table S7). Theoretically, the stringency of ascertaining control subjects could lead to some bias in effect size ([@B44]). In this respect, in addition to the multistage case-control study, an extensive analysis of associated loci in the general population was conducted, which is the strength of the current study. We used the population-based samples (*n* = 12,569) in stage 3 to investigate the effect of control selection criteria on OR in a case-control comparison and found that the ORs in our meta-analysis were almost comparable to those estimated in the general Japanese population (supplementary Table S10). Moreover, with regard to ethnic diversity, linkage disequilibrium in *CDKAL1* and *KCNJ11* is stronger in East Asians (JPT + CHB), whereas linkage disequilibrium in *IGFBP2* and *HHEX* tends to be stronger in Europeans (CEU \[Centre d\'Etude du Polymorphisme Humain (CEPH) subjectsfrom Utah\]) (Supplementary Figure S4); thus, besides the issue of power, the results of the GWA scans in the Japanese population (or East Asians) seem to be useful in terms of interethnic comparison of association signals, which may enhance the power of fine-mapping efforts designed to identify the causal variants ([@B45]).

The tendency of stronger genetic association in the Japanese population is also supported by the concomitant evaluation of multilocus effects. When assuming an additive model, the combined risk of type 2 diabetes can be measured by the sum of the *R* ^2^ values of individual loci. For example, the total variance explained by the seven loci depicted in [Fig. 3](#F3){ref-type="fig"} is 0.030 in the Japanese population and 0.018 in populations of European descent. It remains unknown whether these findings reflect higher heritability of type 2 diabetes in Japanese than in European-descent populations. Because little data are available on the estimation of heritability in the Japanese or East Asian populations, further studies are required to obtain the standardized measures of heritability across different populations by taking into account potential sources of heterogeneity, such as the degree of westernization of lifestyle.

Suggestive evidence of association was identified for SNPs in the *PEPD* gene. *PEPD* plays an important role in collagen metabolism, and some extracellular matrix constituents such as collagen IV have been shown to have a profound impact on insulin secretion ([@B46]). Moreover, enhanced collagen degradation via *PEPD* activity has been reported in diabetic patients ([@B47]). Although there is evidence suggestive of association at *PEPD* in all three stages, the current GWA study by itself could not confirm or refute the evidence; no significant association was found in the previously reported Diabetes Genetics Replication and Meta-Analysis (DIAGRAM) data from Europeans (risk allele frequency = 0.52, OR = 1.03) ([Table 1](#T1){ref-type="table"}) and in the initial screening data of the JSNP (Japanese Single Nucleotide Polymorphisms) scan in the Japanese population (187 casevs. 752 random control subjects; *P* = 0.18 at rs2241380, which is in complete linkage disequilibrium with rs10425678 in *PEPD*; *r* ^2^ = 1.0) ([@B25]).

The number of genes that could account for an appreciable population-attributable fraction of common diseases is under debate ([@B48]). Although the current study detected and/or replicated a total of nine susceptibility loci, including *PEPD* in the Japanese population, a substantial number of SNPs showing some extent of association signals in the first-stage scan remain to be investigated, as reflected by the wide distribution of replicated SNPs with unexamined "gaps" in the lower-left part of the Q-Q plot (supplementary Fig. S7). The ORs corresponding to such unexamined SNPs mostly fall in the range of 1.10--1.25. To assess the statistical power in our GWA scan, we simulated the frequency at which a disease-associated SNP could surpass the cutoff level of the first two stages (stages 1 and 2) (supplementary information and supplementary Table S11). In the current experimental setting, it is likely that \>50% of the susceptibility loci with modest but substantial effects (OR = 1.2--1.3) were unidentified. For example, though not statistically significant, the association of *PPARG* in the Japanese population showed an OR (*P* = 0.06, OR = 1.18 at rs1801282) similar to that in populations of European descent in a meta-analysis, including the current study (supplementary Table S4). Increasing the sample size of the stage 1 panel and/or the number of SNPs genotyped in the second-stage scan would allow us to discover more susceptibility variants, including new population-specific loci, in the Japanese population.

The incidence of type 2 diabetes is escalating to epidemic proportions globally, with a higher acceleration rate in non-European populations ([@B49]). The integration of GWA study results, i.e., a meta-analysis ([@B17]), for both European-descent and non-European populations is necessary for a comprehensive understanding of the genetics of type 2 diabetes, and it will lead to the efficient use of genomic information based on ethnic diversity in clinical research.
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